These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 38409909)

  • 1. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
    Masuda M; Nakagawa R; Kondo T
    Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Reverse-Phase Protein Array for Refining Precision Oncology.
    Masuda M; Yamada T
    Adv Exp Med Biol; 2019; 1188():239-249. PubMed ID: 31820392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling pathway profiling using reverse-phase protein array and its clinical applications.
    Masuda M; Yamada T
    Expert Rev Proteomics; 2017 Jul; 14(7):607-615. PubMed ID: 28621158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.
    Cathcart AM; Smith H; Labrie M; Mills GB
    Expert Rev Proteomics; 2022 Feb; 19(2):115-129. PubMed ID: 35466854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 6. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating proteomics into precision oncology.
    Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
    Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine.
    Masuda M; Yamada T
    Biochim Biophys Acta; 2015 Jun; 1854(6):651-7. PubMed ID: 25448010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling for precision cancer therapies.
    Malone ER; Oliva M; Sabatini PJB; Stockley TL; Siu LL
    Genome Med; 2020 Jan; 12(1):8. PubMed ID: 31937368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omics-based molecular classifications empowering in precision oncology.
    Zhou Z; Lin T; Chen S; Zhang G; Xu Y; Zou H; Zhou A; Zhang Y; Weng S; Han X; Liu Z
    Cell Oncol (Dordr); 2024 Jun; 47(3):759-777. PubMed ID: 38294647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of barriers to implementation of precision oncology in patients with rare cancers.
    Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
    Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing multimodal data integration to advance precision oncology.
    Boehm KM; Khosravi P; Vanguri R; Gao J; Shah SP
    Nat Rev Cancer; 2022 Feb; 22(2):114-126. PubMed ID: 34663944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision oncology using ex vivo technology: a step towards individualised cancer care?
    Williams ST; Wells G; Conroy S; Gagg H; Allen R; Rominiyi O; Helleday T; Hullock K; Pennington CEW; Rantala J; Collis SJ; Danson SJ
    Expert Rev Mol Med; 2022 Oct; 24():e39. PubMed ID: 36184897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.